SCHEMBL6599285

SCHEMBL6599285

ON=C(Cc1ccc(C(F)(F)F)cn1)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
XBP1 P17861 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
DAO P14920 1/20 0.36
KMT2A Q03164 2/20 0.36
PRCP P42785 1/20 0.36
CNR1 P21554 2/20 0.35
CNR2 P34972 1/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PPARD Q03181 1/20 0.35
AHR P35869 1/20 0.34
MEN1 O00255 1/20 0.34
PLA2G1B P04054 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6599282 1.00 NPSR1 (0.43) NPSR1LMNAHPGDALDH1A1MAPT
SCHEMBL6601785 0.89 NPSR1 (0.41) NPSR1LMNAHPGDALDH1A1MAPT
SCHEMBL6601782 0.89 NPSR1 (0.41) NPSR1LMNAHPGDALDH1A1MAPT
SCHEMBL6600003 0.85 NPSR1 (0.45) NPSR1LMNAHPGDALDH1A1MAPT
SCHEMBL6600004 0.85 NPSR1 (0.45) NPSR1LMNAHPGDALDH1A1MAPT
SCHEMBL6600282 0.82 KDM1A (0.42) LMNAHPGDALDH1A1MAPTDAO
SCHEMBL6600278 0.82 KDM1A (0.42) LMNAHPGDALDH1A1MAPTDAO
SCHEMBL3186266 0.81 VNN1 (0.39) NPSR1LMNAL3MBTL1DAOKMT2A
SCHEMBL3186276 0.81 VNN1 (0.39) NPSR1LMNAL3MBTL1DAOKMT2A
SCHEMBL6600125 0.80 MAPK1 (0.38) NPSR1DAOKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756498-B2 REARRANGEMENT OF AZIRINE COMPOUND OR PROTECTED DERIVATIVE THEREOF IN PRESENCE OF TRANSITION METAL CATALYST AND SOLVENT TO PRODUCE PYRAZOLOPYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORPORATION 2004-06-29 US disclosed
EP-1276742-B1 PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2004-06-09 EP disclosed
US-20030212275-A1 PROCESS FOR THE PREPARATION OF CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2003-11-13 US disclosed
EP-1276742-A2 PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-01-22 EP disclosed
WO-2001083479-A2 PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212275-A1 PROCESS FOR THE PREPARATION OF CHEMICAL COMPOUNDS CBR1, C1R, CBR3 NPSR1 407/4885LMNA 2322/4885HPGD 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.